- Home
- PHAR vs ECX Comparison
PHAR vs ECX Comparison
Compare PHAR & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | ECX |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | Netherlands | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 643.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAR | ECX |
|---|---|---|
| Price | $16.31 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $38.00 | $3.20 |
| AVG Volume (30 Days) | 22.5K | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $362,274,000.00 | ★ $822,663,229.00 |
| Revenue This Year | $24.80 | $772.81 |
| Revenue Next Year | $6.84 | $30.47 |
| P/E Ratio | $2,946.57 | ★ N/A |
| Revenue Growth | ★ 26.78 | 6.99 |
| 52 Week Low | $7.50 | $0.76 |
| 52 Week High | $18.12 | $3.25 |
Technical Indicators
Market Signals| Indicator | PHAR | ECX |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 46.53 |
| Support Level | $16.23 | $1.60 |
| Resistance Level | $17.00 | $2.16 |
| Average True Range (ATR) | 0.75 | 0.13 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 36.44 | 37.20 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.